PA
ANIP icon

Profund Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Profund Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Buy
4,167
+346
+9% +$27.8K 0.01% 723
2026
Q1 		$294K Sell
3,821
-31
-0.8% -$2.42K 0.01% 759
2025
Q4 		$304K Buy
3,852
+4
+0.1% +$346 0.01% 863
2025
Q3 		$352K Sell
3,848
-505
-12% -$41.2K 0.01% 662
2025
Q2 		$284K Buy
4,353
+588
+16% +$38.3K 0.01% 714
2025
Q1 		$252K Sell
3,765
-1,206
-24% -$72K 0.01% 776
2024
Q4 		$275K Buy
4,971
+593
+14% +$34K 0.01% 815
2024
Q3 		$261K Buy
4,378
+842
+24% +$51.4K 0.01% 883
2024
Q2 		$225K Buy
+3,536
New +$230K 0.01% 914

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's ANIP Position: Q2 2026 in Review

Profund Advisors increased its ANI Pharmaceuticals (ANIP) stake by 9.1% in Q2 2026, buying an estimated $27.8K and bringing the position to 4,167 shares worth $345K. The position accounts for 0.01% of the portfolio, ranked #723.

Profund Advisors first reported a position in ANIP in Q2 2024 and has held it in 9 quarters since. The position peaked at $352K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Profund Advisors held 4,167 shares of ANI Pharmaceuticals worth $345K as of Q2 2026.
  • Profund Advisors bought 346 ANI Pharmaceuticals shares in Q2 2026, an estimated $27.8K.
  • ANI Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #723 holding.
  • Profund Advisors first reported a position in ANI Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Profund Advisors's ANI Pharmaceuticals position peaked at $352K in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.